{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:53:38Z","timestamp":1791428018998,"version":"4.3.3"},"reference-count":86,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100014823","name":"VGH and UBC Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2023\u2010I2M\u2010C&T\u2010B\u2010045"],"award-info":[{"award-number":["2023\u2010I2M\u2010C&T\u2010B\u2010045"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL14140"],"award-info":[{"award-number":["R01HL14140"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD007632"],"award-info":[{"award-number":["R01FD007632"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune\u2010mediated conditions. MCD can be associated with excessive cytokine production due to a plasma cell neoplasm (MCD\u2013polyneuropathy, organomegaly, endocrinopathy, monoclonal paraprotein, skin changes) or uncontrolled human herpesvirus\u20108 infection (HHV\u20108) (HHV\u20108\u2013positive MCD), but more than half of cases are idiopathic. Although they are all driven by excessive cytokines such as interleukin\u20106 (IL\u20106), patients with idiopathic MCD (iMCD) often present as a diagnostic mystery with heterogeneous symptomatology that can be classified into three subtypes. The three subtypes are iMCD\u2013thrombocytopenia, anasarca, fever, renal dysfunction\/reticulin fibrosis, organomegaly (TAFRO); iMCD\u2013idiopathic plasmacytic lymphadenopathy (IPL); and iMCD\u2013not otherwise specified (NOS). Rapid onset cytokine storm with severe inflammation, anasarca, thrombocytopenia, and small volume lymphadenopathy, similar to hemophagocytic lymphohistiocytosis or sepsis, are the hallmarks of iMCD\u2010TAFRO. Patients with iMCD\u2010IPL present with subacute or chronic lymphadenopathy, anemia of inflammation, and polyclonal hypergammaglobulinemia, often with increased IgG4 in serum and lymph node tissue; these cases can be difficult to distinguish from IgG4\u2010related disease and histiocyte disorders. Those who have iMCD not meeting criteria for TAFRO or IPL have iMCD\u2010NOS, which often mimics indolent lymphoma or autoimmune conditions. Patients with autoimmune disease, lymphoma, and infections can experience Castleman\u2010like changes in reactive lymph nodes, and thus histologic findings must be combined with clinical and laboratory findings to accurately diagnose iMCD. Broadly speaking, treatments for CD can be considered in three categories: immunomodulators such as glucocorticoids, cytokine inhibitors, and sirolimus; antilymphoma therapies such as rituximab, cytotoxic chemotherapy, and BTK inhibitors; and antimyeloma therapies such as thalidomide and bortezomib. The first\u2010line therapy for all subtypes of iMCD is siltuximab, an IL\u20106 antagonist. Patients with refractory disease have numerous treatment options and consulting treatment guidelines as well as consultation with a center with expertise in CD are recommended.<\/jats:p>\n                  <jats:p>\n                    <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                      <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art43269-gra-0001-m.png\">\n                        <jats:alt-text>image<\/jats:alt-text>\n                      <\/jats:graphic>\n                    <\/jats:boxed-text>\n                  <\/jats:p>","DOI":"10.1002\/art.43269","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T02:58:58Z","timestamp":1748919538000},"page":"12-25","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Expert Perspective: Diagnosis and Treatment of Castleman Disease"],"prefix":"10.1002","volume":"78","author":[{"given":"Luke Y. C.","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada, and Division of Hematology, Department of Medicine University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[{"name":"University of Pennsylvania  Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746933"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00317-7"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-23488-0_51"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003607"},{"key":"e_1_2_9_7_1","article-title":"China Castleman Disease Network (CCDN). A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria","volume":"34","author":"Zhang L","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18847"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19966"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018978"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05493-y"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153840"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014391"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013728"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27081"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6732"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000582"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004441"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27574"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31234"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.001"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24242"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810301"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0323-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13702"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377705"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85193-x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210726"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114749"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25123"},{"issue":"5","key":"e_1_2_9_31_1","first-page":"5","article-title":"Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease","volume":"5","author":"Pai RL","year":"2020","journal-title":"JCI Insight"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34873-7"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2412494"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003334"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27507"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012310"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82760-6"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.58931\/cht.2025.4166"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100269"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00856-y"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103137"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-02191-z"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04684-4"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.03.022"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjr\/tqae111"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.24053"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.240947"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00674-7"},{"issue":"12","key":"e_1_2_9_49_1","article-title":"The value of a pet scan in selecting the best lymph node to biopsy, and confirming the diagnosis of idiopathic multicentric Castleman disease with HLH and EBV viremia in a previously healthy adult","volume":"11","author":"Bitektine E","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.004"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-211190"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26292"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27612"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00037-0"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14295"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105731"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678927"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.7976-21"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4005"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000584"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-209280"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19334"},{"issue":"5","key":"e_1_2_9_63_1","first-page":"e365","article-title":"Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management","volume":"8","author":"Zhao EJ","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-862334"},{"key":"e_1_2_9_65_1","volume-title":"Clinical Practice Guidelines in Oncology: Castleman Disease","author":"NCCN","year":"2025"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.02.006"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032200"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126091"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002792"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3347-0"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19827"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-884577"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1999437"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70319-5"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007112"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010745"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-03589-4"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac481"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17868"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00076705"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53413-5"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1528465"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409712"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206712"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102192"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.43269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:30:29Z","timestamp":1769689829000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/art.43269"],"URL":"https:\/\/doi.org\/10.1002\/art.43269","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2025-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}